Yolanda Calle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3097978/publications.pdf

Version: 2024-02-01

55 papers	2,100 citations	394286 19 h-index	233338 45 g-index
56 all docs	56 docs citations	56 times ranked	2974 citing authors

#	Article	IF	Citations
1	Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours. Cells, 2022, 11, 649.	1.8	24
2	Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. Experimental and Molecular Medicine, 2022, 54, 226-238.	3.2	8
3	Invad_2019â€"Mechano-chemical signals in invasion. European Journal of Cell Biology, 2021, 100, 151162.	1.6	0
4	Tackling Ischemic Reperfusion Injury With the Aid of Stem Cells and Tissue Engineering. Frontiers in Physiology, 2021, 12, 705256.	1.3	16
5	Intracellular Staphylococcus aureus Elicits the Production of Host Very Long-Chain Saturated Fatty Acids with Antimicrobial Activity. Metabolites, 2019, 9, 148.	1.3	14
6	Identification of novel targets for host-directed therapeutics against intracellular Staphylococcus aureus. Scientific Reports, 2019, 9, 15435.	1.6	9
7	Host-directed kinase inhibitors act as novel therapies against intracellular Staphylococcus aureus. Scientific Reports, 2019, 9, 4876.	1.6	20
8	TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells. BMC Cancer, 2019, 19, 1214.	1.1	18
9	PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells. Cell Reports, 2019, 29, 3385-3393.e6.	2.9	20
10	Intracellular Staphylococcus aureus Modulates Host Central Carbon Metabolism To Activate Autophagy. MSphere, 2018, 3, .	1.3	56
11	BCRâ€“ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell Death and Disease, 2017, 8, e3114-e3114.	2.7	15
12	Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia, 2014, 28, 1129-1131.	3.3	45
13	Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophages. Journal of Cell Science, 2014, 128, 251-65.	1.2	18
14	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia, 2014, 28, 155-165.	3.3	250
15	Integrin linked kinase (ILK) regulates podosome maturation and stability in dendritic cells. International Journal of Biochemistry and Cell Biology, 2014, 50, 47-54.	1.2	12
16	Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance. Blood, 2013, 122, 3139-3139.	0.6	2
17	Abstract 2142: The nuclear export protein CRM1 (XPO1) regulates multiple myeloma cell growth, osteoclastogenesis, and myeloma-induced osteolysis.. , 2013, , .		1
18	Inhibition Of PI3K Classia Kinases Using GDC0941 Overcomes Protection Of Multiple Myeloma Cells In The Bone Marrow Microenvironment. Blood, 2013, 122, 3169-3169.	0.6	16

#	Article	IF	Citations
19	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood, 2012, 120, 1877-1887.	0.6	162
20	Tyrosine phosphorylation of WASP promotes calpain-mediated podosome disassembly. Haematologica, 2012, 97, 687-691.	1.7	16
21	Fluorescenceâ€based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. British Journal of Haematology, 2012, 157, 564-579.	1.2	17
22	Abstract 2934: Targeting Bruton's tyrosine kinase with PCI-32765 blocks growth and survival of multiple myeloma and WaldenstrÃ¶m macroglobulinemia via potent inhibition of osteoclastogenesis, cytokines/chemokine secretion, and myeloma stem-like cells in the bone marrow microenvironment. , 2012, , .		0
23	Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma. Blood, 2012, 120, 3979-3979.	0.6	0
24	CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis. Blood, 2012, 120, 326-326.	0.6	1
25	CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFÎºB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma. Blood, 2012, 120, 1835-1835.	0.6	1
26	Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMPâ€9. British Journal of Haematology, 2011, 154, 216-222.	1.2	69
27	Role of WASP in cell polarity and podosome dynamics of myeloid cells. European Journal of Cell Biology, 2011, 90, 198-204.	1.6	52
28	The cortactin-binding domain of WIP is essential for podosome formation and extracellular matrix degradation by murine dendritic cells. European Journal of Cell Biology, 2011, 90, 213-223.	1.6	35
29	Podia in Multiple Myeloma (MM) Cells Promote Adhesion with Bone Marrow (BM) Fibroblastic Stromal Cells. Blood, 2011, 118, 626-626.	0.6	1
30	The Wiskott Aldrich Syndrome Protein (WASP) Is Involved in Dexamethasone-Signalling Pathways Leading to Apoptosis of Multiple Myeloma Cells and in Cell Adhesion Mediated Drug Resistance Against Dexamethasone. Blood, 2011, 118, 1809-1809.	0.6	0
31	Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrol^m Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment. Blood, 2011, 118, 883-883.	0.6	1
32	Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib. Blood, 2010, 116, 1931-1931.	0.6	1
33	Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting. Blood, 2010, 116, 982-982.	0.6	0
34	Tyrosine Phosphorylation of WASP Promotes Calpain-Mediated Podosome Disassembly In Myeloid Cells.. Blood, 2010, 116, 1498-1498.	0.6	17
35	Phosphorylation of WASp is a key regulator of activity and stability in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15738-15743.	3.3	51
36	Dual Src/Abl Kinase Targeted Inhibition in Myeloma Microenvironment Promotes Myeloma Cell Apoptosis Both in Vitro and In Vivo.. Blood, 2009, 114, 2813-2813.	0.6	0

#	Article	IF	Citations
37	WASP and WIP regulate podosomes in migrating leukocytes. Journal of Microscopy, 2008, 231, 494-505.	0.8	47
38	Quantifying cellâ€“matrix adhesion dynamics in living cells using interference reflection microscopy. Journal of Microscopy, 2008, 232, 73-81.	0.8	43
39	Improvement of Migratory Defects in a Murine Model of Wiskottâ€“Aldrich Syndrome Gene Therapy. Molecular Therapy, 2008, 16, 836-844.	3.7	35
40	Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. Journal of Experimental Medicine, 2007, 204, 2213-2224.	4.2	158
41	Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. Journal of Cell Biology, 2007, 178, i11-i11.	2.3	0
42	Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma.. Blood, 2007, 110, 4766-4766.	0.6	0
43	Role of Cdc42 in neurite outgrowth of PC12 cells and cerebellar granule neurons. Molecular and Cellular Biochemistry, 2006, 281, 17-25.	1.4	19
44	The leukocyte podosome. European Journal of Cell Biology, 2006, 85, 151-157.	1.6	135
45	WIP Regulates the Stability and Localization of WASP to Podosomes in Migrating Dendritic Cells. Current Biology, 2006, 16, 2337-2344.	1.8	114
46	Inhibition of calpain stabilises podosomes and impairs dendritic cell motility. Journal of Cell Science, 2006, 119, 2375-2385.	1.2	115
47	Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood, 2006, 108, 2182-2189.	0.6	200
48	WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption. Blood, 2004, 103, 3552-3561.	0.6	111
49	Wiskott-Aldrich syndrome protein and the cytoskeletal dynamics of dendritic cells. Journal of Pathology, 2004, 204, 460-469.	2.1	86
50	Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, ACK. Biochemical and Biophysical Research Communications, 2004, 314, 571-579.	1.0	18
51	Tunicamycin Treatment Reduces Intracellular Glutathione Levels: Effect on the Metastatic Potential of the Rhabdomyosarcoma Cell Line S4MH. Chemotherapy, 2000, 46, 408-428.	0.8	10
52	Removal of N-glycans from cell surface proteins induces apoptosis by reducing intracellular glutathione levels in the rhabdomyosarcoma cell line S4MH. Biology of the Cell, 2000, 92, 639-646.	0.7	7
53	In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma. Melanoma Research, 1999, 9, 233-242.	0.6	12
54	Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Clinical and Experimental Metastasis, 1997, 15, 329-337.	1.7	18

#	Article	IF	Citations
55	A simple cell labeling technique by means of lectins linked to fluorochromes for the detection of cells on tissue sections. Biology of the Cell, 1995, 83, 87-92.	0.7	2